DRMAW
Dermata Therapeutics Inc. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-2.16
Beta
0.67
52W High
$0.03
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dermata Therapeutics Inc. Warrant
Dermata Therapeutics Inc. (DRMAW) is an innovative biotechnology company dedicated to developing advanced therapeutics for dermatological conditions, with a strong focus on high-unmet medical needs, particularly acne. Leveraging its proprietary technology platform, Dermata is advancing a promising pipeline of product candidates designed to address the rising demand for effective skin disorder treatments. With a commitment to innovation and a strategic position within the biotechnology landscape, Dermata offers institutional investors a unique opportunity to participate in transformative healthcare solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-4.09M |
| Operating Margin | 0.00% |
| Return on Equity | -103.60% |
| Return on Assets | -52.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.59 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $3.17M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
150.88%
HV 20-Day
166.88%
HV 30-Day
165.41%
HV 60-Day
147.48%
HV Rank
—
Volatility is currently contracting
Data last updated: 7/9/2026